RE: Ta-da23 Oct 2025 08:36
They seem to be sticking to the proposed schedule and with positive results, only repeating earlier post below to help keep track of things - this was from early Aug -
'I can see why management are excited by the ATTC platform utilising small cell molecule, its much more targeted with less toxicity than conventional treatments, really does sound like a step forward for patients, 251 should have a full profile at one of the upcoming conferences.'
From the press release, does sound encouraging for both patients and share holders..
"We are excited to share the progress of HMPL-A251, the first candidate from our ATTC platform. It represents a potentially significant leap forward in addressing the limitations of toxin-based ADCs and narrow therapeutic window of systemic PAM inhibitors. By combining selective PI3K/PIKK inhibition with precise HER2 targeting, HMPL-A251 achieves potent antitumor effects while maintaining a favorable safety profile," said Dr Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED. "The compelling preclinical data presented underscore its potential to redefine treatment for a wide spectrum of cancers, and we are excited to advance HMPL-A251 as well as more ATTC drug candidates toward clinical trials."